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Introduction
Elizabethkingia miricola, a non-fermenting Gram-negative 
rod (NFGNB) was first identified following isolation from 
condensation water in the Russian space laboratory Mir1. 
Originally identified as belonging to the Chryseobacterium 
genus, it has since been re-classified and is closely related to 
Elizabethkingia meningoseptica (previously C. meningosep-
ticum). E. miricola has been demonstrated to be pathogenic, 
with reports of bacteraemia resulting in sepsis and pulmonary 
abscesses2,3. Here, we report the presence of E. miricola in the 
sputum of a patient with cystic fibrosis (CF). To our knowledge, 
this is the first reported case of E. miricola infection in CF. 
Herein, we discuss the case itself and the literature surrounding 
this bacterium to help guide clinicians faced with similar clinical 
scenarios.
Case report
A 49-year-old male with a diagnosis of CF presented to his 
routine CF outpatient department complaining of feeling 
generally unwell. He reported increased cough, but this was 
predominantly non-productive. There was a drop in lung func-
tion, from a baseline forced expiratory volume in one second 
(FEV1) of 2.39 l (65% of the predicted volume) to 2.19 l (60% 
predicted). A sputum sample was obtained following chest 
physiotherapy and sent for routine culture on blood agar, choco-
late agar, Sabouraud agar, Staphylococcus agar, m-Kleb agar 
and cepacia selective agar. Given the non-specific symptoms and 
mild drop in FEV1, it was agreed that no immediate treatment 
was required and a follow-up in 4 weeks’ time was arranged.
Co-morbidities of the patient included osteoporosis and pancre-
atic insufficiency; he was also receiving maintenance treatment 
for allergic bronchopulmonary aspergillosis (ABPA) in the form 
of oral anti-fungal therapy and long-term low-dose oral corticos-
teroids. Cultured respiratory samples in the previous year had 
consistently grown non-epidemic Pseudomonas aeruginosa. 
The patient was receiving a continuous alternating inhaled 
anti-pseudomonal antibiotic regime in the form of tobramycin 
(TOBI 300mg BD) and aztreonam lysine (Cayston 75mg tds). 
The diagnosis of CF was made in adulthood and was based upon 
the presence of bilateral upper zone bronchiectasis on a chest 
CT scan and a raised sweat chloride level following a sweat test. 
Initial genetic testing revealed one copy of the F508del muta-
tion, a second mutation was not identified despite extended 
screening. Family history included a younger sister who had 
died aged 23 years from pancreatitis. Serum immunoglobulin 
testing at the annual screen performed two months prior was 
within normal limits aside from a chronically raised IgG 
anti-aspergillus of 154 mg/L.
A sputum sample taken at the clinic appointment was posi-
tive for P. aeruginosa, and extended 10 day incubation on 
cepacia selective agar resulted in isolation of a cream coloured 
colony. The colony was identified as Elizabethkingia miricola by 
MALDI-TOF (matrix-assisted laser desorption/ionisation time-
of-flight) mass spectrometry. At the next appointment, worsening 
symptoms were observed, including increasing shortness of 
breath, wheeze and productive cough. There was a further 
drop in FEV1 to 1.91 L (52% predicted) (Figure 1). An 
oral course of chloramphenicol (500 mg four times a day) 
Figure 1. Lung function before and after positive sputum culture for Elizabethkingia miricola. ������� ������ ���������� ��� �� � �������      
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along with prednisolone (30 mg daily) for 2 weeks was 
commenced and a further sputum sample was obtained. Chloram-
phenicol was chosen empirically based on a previously observed 
clinical response to the agent and also patient preference to 
avoid ciprofloxacin due to skin photosensitivity. The sputum 
culture taken prior to treatment initiation was again positive for 
P. aeruginosa and E. miricola.
A further 4 weeks later, symptoms were somewhat improved 
and FEV1 had increased to 2.19 l (60% predicted). 
However, another 2 weeks later, symptoms deteriorated again, 
with an associated decline in lung function (FEV1, 1.95 l; 53% 
predicted). Sputum cultures from the previous encounter were 
again positive for P. aeruginosa and E. miricola. Sensitivities 
from previous samples revealed E. miricola resistant to 
meropenem and ceftazidime, but sensitive to piperacillin/ 
tazobactam and ciprofloxacin (CIP). A 2-week course of oral 
CIP (750 mg thrice daily) was therefore commenced.
The patient noted an improvement in symptoms and at the 
next clinic appointment FEV1 had improved to 2.08 l (57% pre-
dicted). Sputum then grew P. aeruginosa and yeast only. A 
further four subsequent sputum samples 1, 4, 8 and 12 months 
later have grown P. aeruginosa but no E. miricola, and lung 
function returned towards baseline.
Discussion
Here, we describe an adult with CF in whom we observed 
clinical and spirometric evidence of pulmonary exacerbation, 
with associated growth of E. miricola in sputum culture. The 
period of clinical instability was observed to coincide with four 
sputum samples culturing E. miricola and improvement was 
seen with treatment. This is the first report of E. miricola in an 
individual with CF, meaning this report should therefore be 
relevant to all CF clinicians and microbiologists involved in the 
care of people with CF.
E. miricola has been described in a number of healthcare 
settings, but not previously in CF. One of the first reports of 
E. miricola infection was of positive growth in blood and 
sputum cultures of a septic patient whom had recently under-
gone a stem-cell transplant for mantle-cell lymphoma. Since 
then it has been reported in only a handful of cases, including 
septicaemia in a young patient with alcoholic pancreatitis and 
in the sputum of a septic patient with pulmonary abscesses2,3. 
A degree of immunocompromise is a unifying feature in 
these cases, and the long-term oral corticosteroids required for 
treatment of ABPA in the present case may have predisposed to 
infection with E. miricola. However, more recently, E. miricola 
has also been identified as causing a UTI in an immunocompetent 
adult4.
All case reports of E. miricola infection mentioned above 
report identification by MALDI-TOF2–4. MALDI-TOF has been 
widely adopted for bacterial identification, facilitating diagnosis 
quickly and reliably. In the CF setting, MALDI-TOF has 
also been shown to be particularly useful in identifying non- 
fermenting gram-negative bacteria, for which classification can 
be difficult using conventional phenotypic approaches5. Given 
the increasing use of MALDI-TOF in clinical microbiology 
laboratories, identification of NFGNB infections is likely to rise. 
Hence, establishing the optimal initial management strategies for 
these infections is important.
In this case, initial empirical treatment with oral chlorampheni-
col did not clear the infection, but treatment with oral CIP (based 
on culture sensitivities) successfully treated the exacerbation. 
Eradication of E. miricola was also observed, with contem-
poraneous clinical improvement. Notably, the sputum culture 
sensitivities revealed that P. aeruginosa was resistant to CIP, 
further supporting the idea that E. miricola had a pathogenic role. 
Our experience of treatment with a fluoroquinolone is in keeping 
with that of previous reports, in which E. miricola bacteraemia 
has been associated with sensitivity to levofloxacin and/or CIP, 
both of which resulted in successful treatment2,6,7. Suscepti-
bility to co-trimoxazole (SXT) has also been reported, and it 
would seem that treatment with fluoroquinolones or SXT is an 
appropriate empirical strategy.
Conclusion
E. miricola appears to have the potential to grow in the CF lung 
and can be associated with pulmonary exacerbation. Given the 
paucity of information on E. miricola infection in CF, we hope 
that the case report and literature review herein are relevant to CF 
clinicians and microbiologists alike. Treatment based on 
culture sensitivity is recommended, but empirical treatment with 
fluoroquinolones may be an appropriate initial strategy if there is 
suspicion of pathogenicity.
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